Other ICR Research
Recent submissions
-
Using proton beam therapy to reduce the toxicity of treatment for breast cancer
(Institute of Cancer Research (University Of London), 2024-06-27)Background and purpose Proton beam therapy (PBT) can deliver radiation dose that conforms more closely to the target than photon treatment, sparing organsat-risk {OAR) thereby reducing late effects of radiotherapy ... -
Elucidating Taxane treatment resistance in lethal prostate cancer
(Institute of Cancer Research (University Of London), 2024-06-17)Despite diagnostic and therapeutic advances, prostate cancer remains the most commonly diagnosed cancer in men, with over 1.2 million new cases worldwide and 20% of cancer-related deaths in men. While initial androgen ... -
A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies.
(ELSEVIER SCI LTD, 2024-05-26)INTRODUCTION: There is a need to improve the outcomes of patients with head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC), especially in recurrent unresectable and metastatic (R/M) setting. ... -
Workshop report: the clinical application of data from multiplex assays of variant effect (MAVEs), 12 July 2023.
(SPRINGERNATURE, 2024-05-01)Clinical classification of genomic variants identified on sequencing is often challenging, with many variants classified as Variants of Uncertain Significance (VUS) on account of insufficient evidence. Advances in sequencing ... -
Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery: A Review of Applicability across Multiple Solid Tumors.
(MDPI, 2024-03-04)This study aims to review the status of the clinical use of monoclonal antibodies (mAbs) that have completed or are in ongoing clinical trials for targeted fluorescence-guided surgery (T-FGS) for the intraoperative ... -
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT.
(NIHR JOURNALS LIBRARY, 2024-03-01)BACKGROUND: Neutropenic sepsis is a common complication of systemic anticancer treatment. There is variation in practice in timing of switch to oral antibiotics after commencement of empirical intravenous antibiotic therapy. ... -
Systems biology of the motif-mediated cell cycle interactome
(Institute of Cancer Research (University Of London), 2024-05-09)The eukaryotic cell cycle is a tightly controlled series of events leading to cell division. It relies on a complex network of regulatory proteins, serving as checkpoints to oversee DNA replication and ensure orderly cell ... -
Prediction of lymph node metastases using immunohistochemical analysis of primary oral tongue squamous cell carcinomas
(Institute of Cancer Research (University Of London), 2024-04-19)We studied archival tissue samples of oral tongue squamous cell carcinoma (OTSCC) for the expression of genes that have been identified, by cDNA microarray studies and previous studies, to be highly discriminatory for lymph ... -
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023.
(SPRINGER, 2024-05-01) -
A time- and single-cell-resolved model of murine bone marrow hematopoiesis
(CELL PRESS, 2024-02-01) -
Systemic biomarkers of immune response in locally-advanced human papillomavirus malignancies treated with radical chemoradiation
(Institute of Cancer Research (University Of London), 2024-02-19)Human papillomavirus (HPV)-driven malignancies exhibit viral oncogenic proteins that act as tumour-specific antigens, making them suitable candidates for monitoring the adaptive immune response during treatment. Chemoradiation ... -
An alternative NURF complex sustains acute myeloid leukemia by regulating the accessibility of insulator regions.
(WILEY, 2023-12-11)Efficient treatment of acute myeloid leukemia (AML) patients remains a challenge despite recent therapeutic advances. Here, using a CRISPRi screen targeting chromatin factors, we identified the nucleosome-remodeling factor ... -
The comprehensive English National Lynch Syndrome Registry: development and description of a new genomics data resource.
(ELSEVIER, 2024-03-01)BACKGROUND: Lynch Syndrome (LS) is a cancer predisposition syndrome caused by constitutional pathogenic variants in the mismatch repair (MMR) genes. To date, fragmentation of clinical and genomic data has restricted ... -
ELM-the Eukaryotic Linear Motif resource-2024 update.
(OXFORD UNIV PRESS, 2024-01-05)Short Linear Motifs (SLiMs) are the smallest structural and functional components of modular eukaryotic proteins. They are also the most abundant, especially when considering post-translational modifications. As well as ... -
Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adults.
(NATURE PORTFOLIO, 2023-12-01)Over one million European children undergo computed tomography (CT) scans annually. Although moderate- to high-dose ionizing radiation exposure is an established risk factor for hematological malignancies, risks at CT ... -
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
(American Association for Cancer Research (AACR), 2024-01-05)PURPOSE: Early results from the phase II MEDIOLA study (NCT02734004) in germline BRCA1- and/or BRCA2-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) showed promising efficacy and safety with olaparib ... -
Radical resection of large metastatic non-functioning pancreatic neuroendocrine carcinoma complicated by splenic vein thrombosis and sinistral portal hypertension.
(Elsevier BV, 2021-04-01)INTRODUCTION AND IMPORTANCE: There are limited reports in the literature of radical surgical resection for pancreatic neuroendocrine carcinoma (PNEC). In patients with non-functioning PNEC (NF-PNEC) within the tail of the ... -
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
(Elsevier BV, 2023-12-08) -
Phosphatase specificity principles uncovered by MRBLE:Dephos and global substrate identification.
(SPRINGERNATURE, 2023-12-06)Phosphoprotein phosphatases (PPPs) regulate major signaling pathways, but the determinants of phosphatase specificity are poorly understood. This is because methods to investigate this at scale are lacking. Here, we develop ... -
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
(BMC, 2023-11-03)BACKGROUND: Ibrutinib, a first-in-class inhibitor of Bruton's tyrosine kinase, is approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease. Based on encouraging preclinical data, ...